Somatropin

Mechanism

Recombinant human growth hormone — the reference standard that all GH secretagogues (ipamorelin, CJC-1295, MK-677, etc.) are compared against. An exact copy of the 191-amino acid protein your pituitary gland naturally produces. FDA-approved for many conditions from childhood growth disorders to adult GH deficiency and AIDS wasting. The gold standard for GH replacement, but requires daily injections, is expensive, and has regulatory and side effect considerations.

Effects

ENDOCRINE SYSTEM: Somatropin is recombinant human growth hormone (rhGH), a 191-amino acid protein identical to pituitary-derived GH. Stimulates hepatic IGF-1 production, the primary mediator of GH's anabolic effects. In GH-deficient children, restores linear growth velocity from 3-4 cm/year to 10-12 cm/year in the first year. In GH-deficient adults, normalizes body composition — reduces visceral adiposity by 10-20%, increases lean mass by 2-5 kg, improves bone mineral density over 12-24 months, and reverses the characteristic central obesity, fatigue, and reduced quality of life [RCT — multiple pivotal trials]. FDA-approved pediatric indications: growth hormone deficiency (GHD), Turner syndrome (45,X — final height gain ~5-8 cm), Prader-Willi syndrome (improves body composition and possibly cognition, but risk of sudden death from respiratory obstruction — sleep study mandatory), small for gestational age (SGA) without catch-up by age 2-4, idiopathic short stature (ISS — controversial, modest gain ~3-5 cm), SHOX deficiency, and Noonan syndrome. FDA-approved adult indications: adult GHD (childhood-onset confirmed by re-testing, or adult-onset from pituitary pathology) and AIDS-associated wasting/cachexia (high-dose, 0.1 mg/kg/day). MUSCULOSKELETAL SYSTEM: Increases nitrogen retention, protein synthesis, and lean body mass. Stimulates chondrocyte proliferation and endochondral ossification (how it drives linear growth). Increases collagen synthesis in tendons and ligaments [animal, clinical]. At supraphysiological doses (performance context, 4-8 IU/day), combined with testosterone produces significant lean mass gains, but GH alone without androgens produces far less muscle hypertrophy than commonly believed — most mass gain is water and connective tissue [RCT — Liu et al., 2008 meta-analysis]. Improves bone mineral density over 18-24 months of treatment in GHD adults [RCT]. METABOLIC SYSTEM: Potent lipolytic — stimulates hormone-sensitive lipase, mobilizes free fatty acids from visceral fat preferentially. Diabetogenic at higher doses: reduces peripheral glucose uptake, increases hepatic glucose output, causes insulin resistance in a dose-dependent manner. At replacement doses (0.2-0.6 mg/day in adults), metabolic effects are generally favorable. At supraphysiological doses, frank diabetes can develop. Increases T4→T3 conversion — can unmask central hypothyroidism (monitor free T4). Reduces cortisol via 11β-HSD1 inhibition — can unmask central adrenal insufficiency. Increases LDL receptor expression, modestly improving lipid profiles in GHD patients [RCT]. INTEGUMENTARY AND OTHER: Improves skin thickness and elasticity (the "anti-aging" appeal), increases sweat gland function, improves hair quality. Renal effects: increases GFR, sodium retention (edema mechanism). Immune function: modest immunomodulatory effects, improved thymic output in aging studies [small clinical]. Side effects are dose-dependent: at replacement doses — mild edema, arthralgias (10-20%), carpal tunnel syndrome (5-10%), transient glucose elevation. At supraphysiological doses — significant edema, carpal tunnel (30-40%), insulin resistance/diabetes, acromegaloid features with chronic use (frontal bossing, jaw growth, soft tissue swelling), potential tumor promotion (theoretical — GH/IGF-1 axis promotes cell proliferation).

Practitioner Guide

DOSING — REPLACEMENT CONTEXT: Pediatric GHD: 0.024-0.034 mg/kg/day SC (25-50 mcg/kg/day), adjusting by growth velocity and IGF-1 levels. Turner syndrome: 0.045-0.050 mg/kg/day (higher doses needed). Prader-Willi: 0.024 mg/kg/day with mandatory sleep study before and during treatment — discontinue if respiratory obstruction develops. Adult GHD: start low at 0.15-0.30 mg/day (NOT weight-based in adults), titrate by 0.1-0.2 mg every 4-6 weeks targeting IGF-1 in the upper half of age-appropriate normal range. Women on oral estrogen require higher doses (estrogen antagonizes hepatic IGF-1 production). AIDS wasting: 0.1 mg/kg/day (Serostim — much higher than replacement). ANTI-AGING / OFF-LABEL: Clinics typically use 0.5-2.0 IU/day (0.17-0.67 mg/day), often 5 days on / 2 days off. This "low-dose" approach aims for IGF-1 in the upper-normal range, minimizing side effects while capturing body composition and quality-of-life benefits. Many patients split into AM injection (mimics physiological AM cortisol-GH interaction). Evening injection before bed is also common (mimics nocturnal GH pulse). PERFORMANCE DOSING: 4-8 IU/day, often split AM/PM, frequently combined with insulin (to counteract GH-induced insulin resistance) and testosterone — high-risk territory with significant side effect burden. ADMINISTRATION: Subcutaneous injection, typically abdomen, thigh, or upper arm. Rotate injection sites to prevent lipohypertrophy. Major brands: Genotropin (Pfizer — powder/pen), Norditropin (Novo Nordisk — premixed pen, no reconstitution, room temperature stable 21 days), Humatrope, Saizen, Omnitrope (biosimilar — often cheapest). MONITORING: IGF-1 levels every 4-8 weeks during titration, then every 6-12 months. Fasting glucose and HbA1c at baseline and every 6 months. Fasting insulin (more sensitive than glucose for early insulin resistance). Free T4 and morning cortisol (GH can unmask central hypothyroidism and adrenal insufficiency). Lipid panel. Bone age in pediatric patients annually. PSA in older males (theoretical concern about GH/IGF-1 and prostate). MRI surveillance in patients with pituitary tumors. COMPARISON TO SECRETAGOGUES: GH secretagogues (CJC-1295, ipamorelin, tesamorelin, sermorelin) stimulate endogenous GH release, preserving pulsatile physiology and negative feedback. Exogenous somatropin delivers flat, non-pulsatile GH, suppressing endogenous production. Secretagogues produce lower but more physiological IGF-1 elevations with fewer side effects (less edema, less insulin resistance). However, secretagogues cannot work in pituitary-level GHD (no GH to release). For true GHD, somatropin is the standard. For anti-aging/optimization in patients with intact pituitaries, secretagogues may be preferable for the pulsatility advantage. COST: Somatropin is expensive — $500-1500+/month depending on brand and dose. Biosimilars (Omnitrope) are cheaper. Compounding pharmacies do not legally compound somatropin (it is a biologic). CONTRAINDICATIONS: Active malignancy, active proliferative diabetic retinopathy, acute critical illness, closed epiphyses (for growth indication), Prader-Willi with severe obesity or respiratory impairment.

Evidence

• A 2024 Update on Growth Hormone Deficiency Syndrome in Adults: From Guidelines to Real Life

  Aversa LSA et al. (2024) — J Clin Med — PMID: 39458028

  This 2024 review summarizes adult growth hormone deficiency diagnosis and treatment literature through August 2024, emphasizing individualized somatropin replacement, quality-of-life monitoring, and the heterogeneity of evidence and treatment protocols in adult GHD.

  moderate

Research Summary

TIER 1: Somatropin has one of the most extensive RCT databases of any peptide therapeutic. Pivotal pediatric GHD trials (Genentech, 1985 — first FDA approval). Multiple large RCTs in adult GHD demonstrating improved body composition, BMD, lipids, and quality of life (KIMS database — >20,000 patients; HypoCCS registry). Turner syndrome RCTs showing ~5-8 cm final height gain. Prader-Willi RCTs showing improved body composition and motor function but with safety signals (sudden death in severely obese PWS patients). AIDS wasting RCTs (Serostim — significant lean mass gain). Liu et al., 2008 — systematic review/meta-analysis of GH in athletes: increased lean mass but no evidence of improved strength or athletic performance. TIER 2: Comprehensive Endocrine Society Clinical Practice Guidelines for GHD diagnosis and treatment (2011, updated 2019). Meta-analyses of GH safety — reassuring data on cancer risk at replacement doses (no increased risk in GHD patients). Reviews of GH in aging (NEJM — Rudman et al., 1990 started the anti-aging craze; subsequent reviews show modest body composition changes with significant side effects in non-GHD elderly). Systematic reviews of GH plus sex steroids in performance context. TIER 3: Anti-aging clinic case series and registry data showing quality-of-life improvements at low doses. International endocrinology society consensus statements. Long-term surveillance from European registries (SAGhE — Safety and Appropriateness of GH treatments in Europe) showing no increased mortality from childhood GH treatment, though slight signal for cerebrovascular events in some analyses. KEY FINDINGS: Somatropin is the gold standard for true GH deficiency — transformative in children, significantly beneficial in adults. In non-GHD populations (anti-aging, performance), the risk-benefit ratio is less favorable: modest body composition changes, real side effects (insulin resistance, edema, carpal tunnel), and theoretical long-term concerns (IGF-1 and cancer risk). The anti-aging appeal is real but overstated. Secretagogues offer a potentially safer alternative for non-GHD optimization. GAPS: Long-term cancer risk in non-GHD users is the biggest unknown. Optimal dosing for anti-aging indications not established by RCTs. Head-to-head comparisons of somatropin vs. secretagogues in non-GHD populations lacking. ACTIVE TRIALS: Long-acting GH formulations (somapacitan, lonapegsomatropin) replacing daily somatropin. Ongoing safety surveillance in large registries.